Cryptophycin anticancer drugs revisited.

Jürgen Rohr

doi:10.1021/cb6004678

Cryptophycin anticancer drugs revisited.

Jürgen Rohr

Research output: Contribution to journal › Comment/debate

18 Scopus citations

Abstract

A recent publication reveals the biosynthetic building blocks, genetic code, and broad substrate tolerance of the enzymes of the cryptophycin biosynthetic pathway. This work lays the foundation for the production of poorly accessible yet very promising members of this family of anticancer compounds from lichen cyanobacterial symbionts. Chemoenzymatic production or precursor-directed biosynthesis might bring candidates from this family of natural products back to clinical trials.

Original language	English
Pages (from-to)	747-750
Number of pages	4
Journal	ACS Chemical Biology
Volume	1
Issue number	12
DOIs	https://doi.org/10.1021/cb6004678
State	Published - Dec 15 2006

ASJC Scopus subject areas

Biochemistry
Molecular Medicine

Access to Document

10.1021/cb6004678

Cite this

@article{15d8b7e0a5f149fb997a149f8ee730ee,

title = "Cryptophycin anticancer drugs revisited.",

abstract = "A recent publication reveals the biosynthetic building blocks, genetic code, and broad substrate tolerance of the enzymes of the cryptophycin biosynthetic pathway. This work lays the foundation for the production of poorly accessible yet very promising members of this family of anticancer compounds from lichen cyanobacterial symbionts. Chemoenzymatic production or precursor-directed biosynthesis might bring candidates from this family of natural products back to clinical trials.",

author = "J{\"u}rgen Rohr",

year = "2006",

month = dec,

day = "15",

doi = "10.1021/cb6004678",

language = "English",

volume = "1",

pages = "747--750",

number = "12",

}

TY - JOUR

T1 - Cryptophycin anticancer drugs revisited.

AU - Rohr, Jürgen

PY - 2006/12/15

Y1 - 2006/12/15

N2 - A recent publication reveals the biosynthetic building blocks, genetic code, and broad substrate tolerance of the enzymes of the cryptophycin biosynthetic pathway. This work lays the foundation for the production of poorly accessible yet very promising members of this family of anticancer compounds from lichen cyanobacterial symbionts. Chemoenzymatic production or precursor-directed biosynthesis might bring candidates from this family of natural products back to clinical trials.

AB - A recent publication reveals the biosynthetic building blocks, genetic code, and broad substrate tolerance of the enzymes of the cryptophycin biosynthetic pathway. This work lays the foundation for the production of poorly accessible yet very promising members of this family of anticancer compounds from lichen cyanobacterial symbionts. Chemoenzymatic production or precursor-directed biosynthesis might bring candidates from this family of natural products back to clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33947546294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947546294&partnerID=8YFLogxK

U2 - 10.1021/cb6004678

DO - 10.1021/cb6004678

M3 - Comment/debate

C2 - 17240971

AN - SCOPUS:33947546294

SN - 1554-8929

VL - 1

SP - 747

EP - 750

JO - ACS Chemical Biology

JF - ACS Chemical Biology

IS - 12

ER -

Cryptophycin anticancer drugs revisited.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this